Related Experiment Videos
Encephalopathy and myoclonus triggered by valproic acid
Andreas Reif1, Christine Leonhard, Rainald Mössner
1Department of Psychiatry, Julius-Maximilians-University of Würzburg, Füchsleinstr. 15, D-97080 Würzburg, Germany. a.reif@gmx.net
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|September 24, 2004
Summary
Valproic acid (VPA) can cause encephalopathy even without high ammonia levels, especially when combined with other psychiatric drugs. Discontinuing VPA resolved symptoms and normalized EEG in a patient with treatment-resistant depression.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Pharmacology
Background:
- Valproic acid (VPA) is a widely used mood stabilizer.
- Concurrent use of VPA with other psychotropic medications may increase adverse event risk.
- Psychotic depression is a challenging diagnosis often requiring polypharmacy.
Observation:
- A 42-year-old male with treatment-resistant psychotic depression was prescribed VPA alongside lithium, clomipramine, flupentixol, and risperidone.
- The patient developed myoclonus, tremor, sedation, and significant EEG background slowing.
- These adverse effects occurred despite normal serum valproic acid and ammonia levels.
Findings:
- The observed symptoms suggest a direct valproic acid-induced encephalopathy.
- The absence of hyperammonemia indicates a mechanism independent of elevated ammonia.
- Psychotropic polypharmacy may have facilitated the VPA-induced encephalopathy.
Implications:
- This case highlights the potential for VPA-induced encephalopathy even with normal ammonia levels.
- Clinicians should consider VPA-induced neurotoxicity in patients on polypharmacy presenting with unexplained neurological symptoms.
- Further research is needed to elucidate the mechanisms of VPA neurotoxicity in the context of psychotropic polypharmacy.